Financials

News Ideas Discussions Technicals Forecast Seasonals

STX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Shield Therapeutics Plc is a commercial stage specialty pharmaceutical company, which engages in addressing iron deficiency with its lead product Accrufer. It operates the Feraccru and PT20 segments. The Feraccru segment refers to the development and commercialization of this product. The PT20 segment related to the development of its secondary asset. The company was founded by Carl Sterritt and Christian Schweiger in 2008 and is headquartered in Gateshead Quays, the United Kingdom.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

STX has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company